SALE
市場調查報告書

全球核醫學市場:至2025年的預測與市場機會

Global Nuclear Medicine Market By Therapy, By Type, By Application, By Therapeutics, By Route of Administration, By End-User, By Region, Forecast & Opportunities, 2025

出版商 TechSci Research 商品編碼 934739
出版日期 內容資訊 英文 110 Pages
商品交期: 請詢問到貨日
價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

全球核醫學市場:至2025年的預測與市場機會 Global Nuclear Medicine Market By Therapy, By Type, By Application, By Therapeutics, By Route of Administration, By End-User, By Region, Forecast & Opportunities, 2025
出版日期: 2020年05月01日內容資訊: 英文 110 Pages
簡介

全球核醫學市場,由於癌症等疾病的發生率和盛行率增加,削減Mo-99需求與供應的缺口的配合措施,以及,各種治療用放射線治療的研究開發活動增加,到2025年預計以驚人的速度成長。還有廣泛使用核醫學分子影像。分子影像,是決定疾病的發病或進展的特定分子流程的生物標記,使用分子的手法。

本報告提供全球核醫學市場的各治療,各類型,各用途,各治療學,各給藥途徑,各終端用戶,各地區調查,市場規模和市場佔有率的預測,推動因素與課題,競爭情形,主要企業簡介等資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 摘要整理

第4章 客戶的迴響

第5章 全球核醫學市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 各治療(放射性碘,放射性抗體,放射性磷,其他)
    • 各類型(SPECT(單一照片發射電腦斷層攝影),PET(正子放出斷層攝影),Alpha發送器,β發送器,近距離放射療法)
    • 各用途(循環系統,呼吸系統,整形外科,神經學,腫瘤學,泌尿科)
    • 各治療學(α粒子發送器,β粒子發送器,歐傑電子發送器)
    • 各給藥途徑(口服,點滴,經鼻)
    • 各終端用戶(醫院,診斷中心,其他)
    • 各企業(2019年)
    • 各地區
  • 市場魅力指數

第6章 亞太地區的核醫學市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 各治療
    • 各類型
    • 各用途
    • 各治療學
    • 各給藥途徑
    • 各終端用戶
    • 各國
  • 市場魅力指數
  • 亞太地區:各國分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 新加坡
    • 澳洲

第7章 歐洲的核醫學市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 各治療
    • 各類型
    • 各用途
    • 各治療學
    • 各給藥途徑
    • 各終端用戶
    • 各國
  • 市場魅力指數
  • 歐洲:各國分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 俄羅斯
    • 西班牙

第8章 北美的核醫學市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 各治療
    • 各類型
    • 各用途
    • 各治療學
    • 各給藥途徑
    • 各終端用戶
    • 各國
  • 市場魅力指數
  • 北美:各國分析
    • 美國
    • 墨西哥
    • 加拿大

第9章 南美的核醫學市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 各治療
    • 各類型
    • 各用途
    • 各治療學
    • 各給藥途徑
    • 各終端用戶
    • 各國
  • 市場魅力指數
  • 南美:各國分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章 中東、非洲的核醫學市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 各治療
    • 各類型
    • 各用途
    • 各治療學
    • 各給藥途徑
    • 各終端用戶
    • 各國
  • 市場魅力指數
  • 中東、非洲地區:各國分析
    • 南非
    • 沙烏地阿拉伯
    • UAE

第11章 市場動態

  • 促進因素
  • 課題

第12章 市場趨勢與發展

第13章 競爭情形

  • 競爭的展望
  • 主要企業簡介
    • Cardinal Health
    • Curium
    • Lantheus
    • Bracco
    • Advanced Accelerator Applications
    • NTP Radioisotopes
    • Eckert & Ziegler
    • Jubilant DraxImage
    • GE Healthcare
    • Siemens Healthineers
    • Rotem Industries
    • Eczacibasi-Monrol
    • IBA Group
    • Ire-Elit
    • Lucerno Dynamics
    • Positron Corporation
    • NorthStar Medical Radioisotopes
    • Pharmalucence
    • Norgine
    • Roche

第14章 策略性推薦事項

第15章 關於公司和免責聲明

目錄
Product Code: 4562

Global nuclear medicine market is estimated to grow at an impressive rate during the forecast period owing to increasing incidence and prevalence of diseases like cancer, initiatives to reduce the demand and supply gap of Mo-99 and increasing research and development activities in radiotherapy to treat various diseases. Furthermore, nuclear medicines are extensively being used in molecular imaging, which is a technique involving molecules as biomarkers for specific molecular processes that determines the onset or progress of a disease.

Nuclear medicines are convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. Due to this major factor, chemotherapy methods are being replaced by radiopharmaceuticals or nuclear medicines for cancer treatment. They are also used in applications such as lymphoma and bone metastasis. Some of the nuclear medicines used in diagnostic procedures are F-18, Tc-99, Ga-67, and I-123 while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutics procedures. These factors are anticipated to drive global nuclear medicine market until 2025.

Apart from above mentioned growth factors, the global nuclear medicine market also faces some restrains. Short half-life of nuclear medicines or radiopharmaceuticals reduces their potential adoption. Other restraining factors include supply shortages, logistical difficulties, and limited number of trained medical personnel.

The global nuclear medicine market is segmented based on therapy, type, application, therapeutics, route of administration, end-user and region. Based on application, the global nuclear medicine market is segmented into cardiology, respiratory, orthopaedics, neurology, oncology and urology. Among them, the oncology segment accounts for the major market share due to increasing prevalence of cancer worldwide. Based on type, the nuclear medicine market is segmented into SPECT, PET, alpha-emitters, beta-emitters and brachytherapy. The SPECT segment accounts for the largest market share and is expected to hold its dominance in the coming years owing to low cost and wide usage in different applications.

Major players operating in the global nuclear medicine market include Cardinal Health, Curium, Lantheus, Bracco, Advanced Accelerator Applications, NTP Radioisotopes, Eckert & Ziegler, Jubilant DraxImage, GE Healthcare, Siemens Healthineers, Rotem Industries, Eczacibasi-Monrol, IBA Group, Ire-Elit, Lucerno Dynamics, Positron Corporation, NorthStar Medical Radioisotopes, Pharmalucence, Norgine, Roche and others. Key market players are implementing activities like product developments, business expansion, and collaborative development to maintain significant share in the market for nuclear medicine.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2025

Objective of the Study

  • To analyze and forecast the market size of global nuclear medicine market.
  • To classify and forecast global nuclear medicine market based on therapy, type, application, therapeutics, route of administration, end-user, company and regional distribution.
  • To identify drivers and challenges for global nuclear medicine market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global nuclear medicine market.
  • To conduct pricing analysis for global nuclear medicine market.
  • To identify and analyze the profile of leading players operating in global nuclear medicine market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global nuclear medicine market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience

  • Nuclear medicine manufacturer, suppliers, distributors and other stakeholders
  • Hospitals & Clinics
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to nuclear medicine
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope

In this report, global nuclear medicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Therapy:

Radioactive Iodine

Radioactive Antibodies

Radioactive Phosphorus

Others

  • Market, By Type:

SPECT (Single Photo Emission Computed Tomography)

PET (Positron Emission Tomography)

Alpha-emitters

Beta-emitters

Brachytherapy

  • Market, By Application:

Cardiology

Respiratory

Orthopaedics

Neurology

Oncology

Urology

  • Market, By Therapeutics:

Alpha Particle Emitters

Beta Particle Emitters

Auger Electron Emitters

  • Market, By Route of Administration:

Oral

Intravenous

Nasal

  • Market, By End-User:

Hospitals

Diagnostic Centers

Others

  • Market, By Region:

Asia-Pacific

Europe

North America

South America

Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global nuclear medicine market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Nuclear Medicine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value & Volume
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy (Radioactive Iodine, Radioactive Antibodies, Radioactive Phosphorus, Others
    • 5.2.2. By Type (SPECT (Single photo emission computed tomography), PET (Positron emission tomography), Alpha-emitters, Beta-emitters, Brachytherapy)
    • 5.2.3. By Application (Cardiology, Respiratory, Orthopaedics, Neurology, Oncology, Urology)
    • 5.2.4. By Therapeutics (Alpha Particle Emitters, Beta Particle Emitters, Auger Electron Emitters)
    • 5.2.5. By Route of Administration (Oral, Intravenous, Nasal)
    • 5.2.6. By End-User (Hospitals, Diagnostic centers, Others)
    • 5.2.7. By Company (2019)
    • 5.2.8. By Region
  • 5.3. Market Attractiveness Index

6. Asia-Pacific Nuclear Medicine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy
    • 6.2.2. By Type
    • 6.2.3. By Application
    • 6.2.4. By Therapeutics
    • 6.2.5. By Route of Administration
    • 6.2.6. By End-User
    • 6.2.7. By Country
  • 6.3. Market Attractiveness Index
  • 6.4. Asia-Pacific: Country Analysis
    • 6.4.1. China Nuclear Medicine Market Outlook
      • 6.4.1.1. Market Size & Forecast
        • 6.4.1.1.1. By Value
      • 6.4.1.2. Market Share & Forecast
        • 6.4.1.2.1. By Therapy
        • 6.4.1.2.2. By Type
        • 6.4.1.2.3. By Application
        • 6.4.1.2.4. By Therapeutics
        • 6.4.1.2.5. By Route of Administration
        • 6.4.1.2.6. By End-User
    • 6.4.2. India Nuclear Medicine Market Outlook
      • 6.4.2.1. Market Size & Forecast
        • 6.4.2.1.1. By Value
      • 6.4.2.2. Market Share & Forecast
        • 6.4.2.2.1. By Therapy
        • 6.4.2.2.2. By Type
        • 6.4.2.2.3. By Application
        • 6.4.2.2.4. By Therapeutics
        • 6.4.2.2.5. By Route of Administration
        • 6.4.2.2.6. By End-User
    • 6.4.3. Japan Nuclear Medicine Market Outlook
      • 6.4.3.1. Market Size & Forecast
        • 6.4.3.1.1. By Value
      • 6.4.3.2. Market Share & Forecast
        • 6.4.3.2.1. By Therapy
        • 6.4.3.2.2. By Type
        • 6.4.3.2.3. By Application
        • 6.4.3.2.4. By Therapeutics
        • 6.4.3.2.5. By Route of Administration
        • 6.4.3.2.6. By End-User
    • 6.4.4. South Korea Nuclear Medicine Market Outlook
      • 6.4.4.1. Market Size & Forecast
        • 6.4.4.1.1. By Value
      • 6.4.4.2. Market Share & Forecast
        • 6.4.4.2.1. By Therapy
        • 6.4.4.2.2. By Type
        • 6.4.4.2.3. By Application
        • 6.4.4.2.4. By Therapeutics
        • 6.4.4.2.5. By Route of Administration
        • 6.4.4.2.6. By End-User
    • 6.4.5. Singapore Nuclear Medicine Market Outlook
      • 6.4.5.1. Market Size & Forecast
        • 6.4.5.1.1. By Value
      • 6.4.5.2. Market Share & Forecast
        • 6.4.5.2.1. By Therapy
        • 6.4.5.2.2. By Type
        • 6.4.5.2.3. By Application
        • 6.4.5.2.4. By Therapeutics
        • 6.4.5.2.5. By Route of Administration
        • 6.4.5.2.6. By End-User
    • 6.4.6. Australia Nuclear Medicine Market Outlook
      • 6.4.6.1. Market Size & Forecast
        • 6.4.6.1.1. By Value
      • 6.4.6.2. Market Share & Forecast
        • 6.4.6.2.1. By Therapy
        • 6.4.6.2.2. By Type
        • 6.4.6.2.3. By Application
        • 6.4.6.2.4. By Therapeutics
        • 6.4.6.2.5. By Route of Administration
        • 6.4.6.2.6. By End-User

7. Europe Nuclear Medicine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Type
    • 7.2.3. By Application
    • 7.2.4. By Therapeutics
    • 7.2.5. By Route of Administration
    • 7.2.6. By End-User
    • 7.2.7. By Country
  • 7.3. Market Attractiveness Index
  • 7.4. Europe: Country Analysis
    • 7.4.1. France Nuclear Medicine Market Outlook
      • 7.4.1.1. Market Size & Forecast
        • 7.4.1.1.1. By Value
      • 7.4.1.2. Market Share & Forecast
        • 7.4.1.2.1. By Therapy
        • 7.4.1.2.2. By Type
        • 7.4.1.2.3. By Application
        • 7.4.1.2.4. By Therapeutics
        • 7.4.1.2.5. By Route of Administration
        • 7.4.1.2.6. By End-User
    • 7.4.2. Germany Nuclear Medicine Market Outlook
      • 7.4.2.1. Market Size & Forecast
        • 7.4.2.1.1. By Value
      • 7.4.2.2. Market Share & Forecast
        • 7.4.2.2.1. By Therapy
        • 7.4.2.2.2. By Type
        • 7.4.2.2.3. By Application
        • 7.4.2.2.4. By Therapeutics
        • 7.4.2.2.5. By Route of Administration
        • 7.4.2.2.6. By End-User
    • 7.4.3. United Kingdom Nuclear Medicine Market Outlook
      • 7.4.3.1. Market Size & Forecast
        • 7.4.3.1.1. By Value
      • 7.4.3.2. Market Share & Forecast
        • 7.4.3.2.1. By Therapy
        • 7.4.3.2.2. By Type
        • 7.4.3.2.3. By Application
        • 7.4.3.2.4. By Therapeutics
        • 7.4.3.2.5. By Route of Administration
        • 7.4.3.2.6. By End-User
    • 7.4.4. Italy Nuclear Medicine Market Outlook
      • 7.4.4.1. Market Size & Forecast
        • 7.4.4.1.1. By Value
      • 7.4.4.2. Market Share & Forecast
        • 7.4.4.2.1. By Therapy
        • 7.4.4.2.2. By Type
        • 7.4.4.2.3. By Application
        • 7.4.4.2.4. By Therapeutics
        • 7.4.4.2.5. By Route of Administration
        • 7.4.4.2.6. By End-User
    • 7.4.5. Russia Nuclear Medicine Market Outlook
      • 7.4.5.1. Market Size & Forecast
        • 7.4.5.1.1. By Value
      • 7.4.5.2. Market Share & Forecast
        • 7.4.5.2.1. By Therapy
        • 7.4.5.2.2. By Type
        • 7.4.5.2.3. By Application
        • 7.4.5.2.4. By Therapeutics
        • 7.4.5.2.5. By Route of Administration
        • 7.4.5.2.6. By End-User
    • 7.4.6. Spain Nuclear Medicine Market Outlook
      • 7.4.6.1. Market Size & Forecast
        • 7.4.6.1.1. By Value
      • 7.4.6.2. Market Share & Forecast
        • 7.4.6.2.1. By Therapy
        • 7.4.6.2.2. By Type
        • 7.4.6.2.3. By Application
        • 7.4.6.2.4. By Therapeutics
        • 7.4.6.2.5. By Route of Administration
        • 7.4.6.2.6. By End-User

8. North America Nuclear Medicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Type
    • 8.2.3. By Application
    • 8.2.4. By Therapeutics
    • 8.2.5. By Route of Administration
    • 8.2.6. By End-User
    • 8.2.7. By Country
  • 8.3. Market Attractiveness Index
  • 8.4. North America: Country Analysis
    • 8.4.1. United States Nuclear Medicine Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Therapy
        • 8.4.1.2.2. By Type
        • 8.4.1.2.3. By Application
        • 8.4.1.2.4. By Therapeutics
        • 8.4.1.2.5. By Route of Administration
        • 8.4.1.2.6. By End-User
    • 8.4.2. Mexico Nuclear Medicine Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Therapy
        • 8.4.2.2.2. By Type
        • 8.4.2.2.3. By Application
        • 8.4.2.2.4. By Therapeutics
        • 8.4.2.2.5. By Route of Administration
        • 8.4.2.2.6. By End-User
    • 8.4.3. Canada Nuclear Medicine Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Therapy
        • 8.4.3.2.2. By Type
        • 8.4.3.2.3. By Application
        • 8.4.3.2.4. By Therapeutics
        • 8.4.3.2.5. By Route of Administration
        • 8.4.3.2.6. By End-User

9. South America Nuclear Medicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Type
    • 9.2.3. By Application
    • 9.2.4. By Therapeutics
    • 9.2.5. By Route of Administration
    • 9.2.6. By End-User
    • 9.2.7. By Country
  • 9.3. Market Attractiveness Index
  • 9.4. South America: Country Analysis
    • 9.4.1. Brazil Nuclear Medicine Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Therapy
        • 9.4.1.2.2. By Type
        • 9.4.1.2.3. By Application
        • 9.4.1.2.4. By Therapeutics
        • 9.4.1.2.5. By Route of Administration
        • 9.4.1.2.6. By End-User
    • 9.4.2. Argentina Nuclear Medicine Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Therapy
        • 9.4.2.2.2. By Type
        • 9.4.2.2.3. By Application
        • 9.4.2.2.4. By Therapeutics
        • 9.4.2.2.5. By Route of Administration
        • 9.4.2.2.6. By End-User
    • 9.4.3. Colombia Nuclear Medicine Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Therapy
        • 9.4.3.2.2. By Type
        • 9.4.3.2.3. By Application
        • 9.4.3.2.4. By Therapeutics
        • 9.4.3.2.5. By Route of Administration
        • 9.4.3.2.6. By End-User

10. Middle East and Africa Nuclear Medicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy
    • 10.2.2. By Type
    • 10.2.3. By Application
    • 10.2.4. By Therapeutics
    • 10.2.5. By Route of Administration
    • 10.2.6. By End-User
    • 10.2.7. By Country
  • 10.3. Market Attractiveness Index
  • 10.4. MEA: Country Analysis
    • 10.4.1. South Africa Nuclear Medicine Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Therapy
        • 10.4.1.2.2. By Type
        • 10.4.1.2.3. By Application
        • 10.4.1.2.4. By Therapeutics
        • 10.4.1.2.5. By Route of Administration
        • 10.4.1.2.6. By End-User
    • 10.4.2. Saudi Arabia Nuclear Medicine Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Therapy
        • 10.4.2.2.2. By Type
        • 10.4.2.2.3. By Application
        • 10.4.2.2.4. By Therapeutics
        • 10.4.2.2.5. By Route of Administration
        • 10.4.2.2.6. By End-User
    • 10.4.3. UAE Nuclear Medicine Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Therapy
        • 10.4.3.2.2. By Type
        • 10.4.3.2.3. By Application
        • 10.4.3.2.4. By Therapeutics
        • 10.4.3.2.5. By Route of Administration
        • 10.4.3.2.6. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape

  • 13.1. Competition Outlook
  • 13.2. Players Profiled (Leading Companies)
    • 13.2.1. Cardinal Health
    • 13.2.2. Curium
    • 13.2.3. Lantheus
    • 13.2.4. Bracco
    • 13.2.5. Advanced Accelerator Applications
    • 13.2.6. NTP Radioisotopes
    • 13.2.7. Eckert & Ziegler
    • 13.2.8. Jubilant DraxImage
    • 13.2.9. GE Healthcare
    • 13.2.10. Siemens Healthineers
    • 13.2.11. Rotem Industries
    • 13.2.12. Eczacibasi-Monrol
    • 13.2.13. IBA Group
    • 13.2.14. Ire-Elit
    • 13.2.15. Lucerno Dynamics
    • 13.2.16. Positron Corporation
    • 13.2.17. NorthStar Medical Radioisotopes
    • 13.2.18. Pharmalucence
    • 13.2.19. Norgine
    • 13.2.20. Roche

14. Strategic Recommendations

15. About Us & Disclaimer